GOAL OF WORK: We compared the efficacy of ceftriaxone (CA regimen) and piperacillin-tazobactam (PTA regimen) in association with amikacin in the treatment of febrile episodes in severely neutropenic hematological patients. PATIENTS AND METHODS: A total of 252 febrile episodes in 224 patients were randomized. MAIN RESULTS: The CA regimen was effective in 62/122 evaluable episodes (50.8%), and the PTA regimen was effective in 64/121 (52.9%; P>0.2). Median time to failure was 4 and 5 days (P>0.1). Further infections developed in 21/122 episodes (17.2%) with the CA regimen and in 12/121 (9.9%) with the PTA regimen (P=0.06). The overall mortality at the end of the febrile episode was 11/243 (4.5%); seven deaths were considered to be related to infection. CONCLUSIONS: Patients treated with piperacillin-tazobactam and amikacin tended to become afebrile sooner and to suffer a lower rate of further infections, even though our data did not show any statistically significant differences between the two groups.
RCT Entities:
GOAL OF WORK: We compared the efficacy of ceftriaxone (CA regimen) and piperacillin-tazobactam (PTA regimen) in association with amikacin in the treatment of febrile episodes in severely neutropenic hematologicalpatients. PATIENTS AND METHODS: A total of 252 febrile episodes in 224 patients were randomized. MAIN RESULTS: The CA regimen was effective in 62/122 evaluable episodes (50.8%), and the PTA regimen was effective in 64/121 (52.9%; P>0.2). Median time to failure was 4 and 5 days (P>0.1). Further infections developed in 21/122 episodes (17.2%) with the CA regimen and in 12/121 (9.9%) with the PTA regimen (P=0.06). The overall mortality at the end of the febrile episode was 11/243 (4.5%); seven deaths were considered to be related to infection. CONCLUSIONS:Patients treated with piperacillin-tazobactam and amikacin tended to become afebrile sooner and to suffer a lower rate of further infections, even though our data did not show any statistically significant differences between the two groups.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: A Del Favero; F Menichetti; P Martino; G Bucaneve; A Micozzi; G Gentile; P Furno; D Russo; D D'Antonio; P Ricci; B Martino; F Mandelli Journal: Clin Infect Dis Date: 2001-09-14 Impact factor: 9.079
Authors: A G Freifeld; T Walsh; D Marshall; J Gress; S M Steinberg; J Hathorn; M Rubin; P Jarosinski; V Gill; R C Young Journal: J Clin Oncol Date: 1995-01 Impact factor: 44.544
Authors: A Simon; T Lehrnbecher; U Bode; A H Groll; L Tramsen; R Wieland; E Molitor; G Fleischhack; H J Laws Journal: Eur J Clin Microbiol Infect Dis Date: 2007-11 Impact factor: 5.103